Venice (Italy), October 24-27, 2004

ADVANCE PROGRAM

DRUGS AFFECTING LIPID METABOLISM

Lorenzini Foundation Symposium 299

Phone: +39 041 562 6527, Fax: +39 041 562 6520, 18
XV International Symposium on
“DRUGS AFFECTING
LIPID METABOLISM”
Venice, October 24-27, 2004

SCI ENTI FI C COMMITTEEES

CHAIRPERSONS
Gotto A.M., Jr. (USA) - Paoletti R. (Italy)

SCI ENTI FI C SECRETARIES
Catapano A.L. (Italy) - Ballantyne C.M. (USA)

INTERNATIONAL ADVISORY BOARD
Assmann G. (Germany) - Avogaro A. (Italy) - Badimon L. (Spain) - Barter P. (Australia) - Beisiegel U. (Germany) - Brewer H.B., Jr. (USA) - Calandra S. (Italy) - Carmena R. (Spain) - Chiarello M. (Italy) - Corsini A. (Italy) - Crea F. (Italy) - Crepaldi G. (Italy) - Davignon J. (Canada) - Ding P.Y.-A. (ROC) - Faergeman O. (Denmark) - Ferrannini E. (Italy) - Franceschini G. (Italy) - Fruchart J.-C. (France) - Galli C. (Italy) - Gensini G.F. (Italy) - Ginsberg H.N. (USA) - Greten H. (Germany) - Grundy S.M. (USA) - Hajjar D.P. (USA) - Hamsten A. (Sweden) - Juhan-Vague I. (France) - Kastelein J.J.P. (The Netherlands) - Kita T. (Japan) - Leitersdorf E. (Israel) - Lenfant C. (USA) - Libby P. (USA) - Maggioni A.P. (Italy) - Mancia G. (Italy) - Mancini M. (Italy) - Marchioli R. (Italy) - Matsuzawa Y. (Japan) - Mezzetti A. (Italy) - Naruszewicz M. (Poland) - Nissen S.E. (USA) - Noseda G. (Switzerland) - Notarbartolo A. (Italy) - Novo S. (Italy) - Olsson A.G. (Sweden) - Patrono C. (Italy) - Pedersen T. (Norway) - Pitt B. (USA) - Rader D.J. (USA) - Reddy K.S. (India) - Ridker P. (USA) - Rubba P. (Italy) - Sacks F.M. (USA) - Sans S. (Spain) - Santamarina-Fojo S. (USA) - Schaefer E.J. (USA) - Shepherd J. (UK) - Sirtori C.R. (Italy) - Stein E.A. (USA) - Stein Y. (Israel) - Tall A. (USA) - Tokgozoglu L. (Turkey) - Tonkin A. (Australia) - Tremoli E. (Italy) - Vella S. (Italy) - Violi F. (Italy) - Volpe M. (Italy) - Wenger N.K. (USA) - Zambon A. (Italy)

LOCAL PROGRAMME COMMITTEE
Bellosta S. (Italy) - Calabresi L. (Italy) - Camera M. (Italy) - Caruso D. (Italy) - Chiesa G. (Italy) - Cignarella A. (Italy) - Crestani M. (Italy) - Ferri N. (Italy) - Maggi F. (Italy) - Norata D. (Italy) - Sironi L. (Italy) - Visioli F. (Italy)
SCIENTIFIC SPONSORSHIPS

JOINTLY SPONSORED BY
International Atherosclerosis Society (IAS)
National Heart, Lung, and Blood Institute (NHLBI/NIH)
Fondazione Giovanni Lorenzini Medical Sciences Foundation
Giovanni Lorenzini Medical Foundation
Italian Heart Foundation
World Heart Federation (WHF)

UNDER THE AUSPICES OF
American Heart Association
  Council on Arteriosclerosis, Thrombosis, and Vascular Biology
  Council on High Blood Pressure Research
  Council on Nutrition, Physical Activity, and Metabolism
  Stroke Council
Asian Pacific Society of Atherosclerosis and Vascular Diseases (APSAVD)
European Association for the Study of Diabetes (EASD)
European Atherosclerosis Society (EAS)
European Federation for Internal Medicine (EFIM)
European Federation of Pharmacological Sciences (EPHAR)
European Lipoprotein Club (ELC)
European Society for Clinical Investigation (ESCI)
European Society of Hypertension (ESH)
International Conference on the Bioscience of Lipids (ICBL)
International Society for the Study of Fatty Acids and Lipids (ISSFAL)
International Society of Thrombosis and Haemostasis (ISTH)
International Task Force for Prevention of Coronary Heart Disease
Italian Association of Hospital Cardiologists (ANMCO)
Italian Federation of Cardiology (FIC)
Italian Out-Patient Cardiologists Association (ANCE)
Italian Society for Cardiovascular Prevention (S.I.PRE.C.)
Italian Society for the Study of Arteriosclerosis (SISA)
Italian Society for the Study of Haemostasis and Thrombosis (SISET)
Italian Society of Diabetology (SID)
Italian Society of Pharmacology (SIF)
Italian Society of Internal Medicine (SIMI)
The American Society of Hypertension (ASH)
SUNDAY, OCTOBER 24, 2004

OPENING REMARKS

PLENARY SESSION
MECHANISMS CONTROLLING LIPID HOMEOSTASIS
9:00 – 10:30 a.m.

H.B. Brewer, Jr. (Bethesda, USA)
NEW INSIGHTS INTO LIPOPROTEIN METABOLISM AND TARGETS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE

J.-C. Fruchart (Lille, France)
TRANSCRIPTION FACTORS: FROM TRANSCRIPTIONAL ACTIVATION TO CLINICAL APPLICATION

G. Assmann (Munster, Germany)
ABC GENES AND LIPID HOMEOSTASIS

MONDAY, OCTOBER 25, 2004

PLENARY SESSION
MODULATION OF LDL AND HDL CHOLESTEROL
8:30 – 10:30 a.m.

R. Collins (Oxford, UK)
CLINICAL TRIALS WITH STATINS: WHAT WE HAVE LEARNT

J. Davignon (Montreal, Canada)
PLEIOTROPIC EFFECTS OF LIPID LOWERING

J.J.P. Kastelein (Amsterdam, The Netherlands)
THE CURRENT AND FUTURE MODULATION OF HDL

C.R. Sirtori (Milan, Italy)
APO A-I MILANO AND THE NEW ERA OF HDL THERAPY
TUESDAY, OCTOBER 26, 2004

PLENARY SESSION
FORMATION AND PROGRESSION OF THE ATHEROSCLEROTIC PLAQUE
8:30 – 10:30 a.m.

P. Libby (Boston, USA)
THE PATHOPHYSIOLOGY OF THE ATHEROSCLEROTIC PLAQUE

M.-R. Taskinen (Helsinki, Finland)
DIABETES AND ATHEROSCLEROSIS: NOVEL POTENTIAL TARGETS FOR THERAPY

G. Mancia (Monza, Italy)
CARDIOVASCULAR PROTECTION BY ANTIHYPERTENSIVE TREATMENT. EVIDENCE FROM CONTROLLED TRIALS

S.M. Grundy (Dallas, USA)
ATHEROSCLEROSIS AND THE METABOLIC SYNDROME

PLENARY LECTURE
11:00 – 11:40 a.m.

A.M. Gotto, Jr. (New York, USA)
PERSPECTIVES ON STATINS IN CARDIOVASCULAR MEDICINE AND INFLAMMATORY DISEASES

WEDNESDAY, OCTOBER 27, 2004

PLENARY SESSION
SURROGATE ENDPOINTS IN THE EVALUATION OF LIPID LOWERING THERAPY
8:30 – 10:30 a.m.

R. Corti (Zurich, Switzerland)
EFFECTS OF LIPOID LOWERING ON ATHEROSCLEROTIC PLAQUES: IN VIVO DATA BY MRI

S.E. Nissen (Cleveland, USA)
INTRAVASCULAR ULTRASOUND: INSIGHTS INTO ATHEROSCLEROSIS

E. Tremoli (Milan, Italy)
NON INVASIVE METHODOLOGY: INTIMA MEDIA THICKNESS

S. Achenbach (Erlangen, Germany)
CORONARY PLAQUE IMAGING WITH CT TECHNIQUES
ROUND TABLE
GUIDELINES AND TARGET OF LIPID LOWERING THERAPY
11:00 a.m. – 12:30 pm

Chairs: A.M. Gotto, Jr. (New York, NY, USA)
R. Paoletti (Milan, Italy)

S.M. Grundy (Dallas, TX, USA)
THE CURRENT USA PERSPECTIVE

O. Faergeman (Århus, Denmark)
A EUROPEAN PERSPECTIVE

G. Assmann (Munster, Germany)
THE VIEW OF THE INTERNATIONAL TASK FORCE FOR PREVENTION OF CORONARY HEART DISEASE

Y. Matsuzawa (Osaka, Japan)
THE CURRENT ASIAN-PACIFIC PERSPECTIVE
The Scientific Program will also include:

A) WORKSHOPS (Invitd Lectures and Selected Oral Communications) (Preliminary Program)

- **LIPOPROTEIN MODIFICATION IN ATHEROSCLEROSIS**
  - **S. Fazio** (Nashville, TN, USA)
  - HDL MODIFICATIONS, MACROPHAGES, AND ATHEROGENESIS

- **DIABETES AND HYPERGLYCEMIA**
  - **H. Yki-Järvinen** (Helsinki, Finland)
  - THE FATTY LIVER: A KEY TO INSULIN RESISTANCE IN BOTH OBESITY AND LIPOATROPHY
  - **H. Ginsberg** (New York, NY, USA)
  - INSULIN RESISTANCE AND DYSLIPIDEMIA: THE ROLE OF PPAR GAMMA

- **CHOLESTEROL ABSORPTION AND METABOLISM, INCLUDING ABC TRANSPORTERS**
  - **H.H. Hobbs** (Dallas, TX, USA)
  - GENETICS DEFENSES AGAINST STEROL ACCUMULATION
  - **G. Schmitz** (Regensburg, Germany)
  - TRANSCRIPTIONAL CONTROL OF ABCA1 AND HDL METABOLISM

- **LIPOPROTEIN PHYSIOLOGY: PARTICLES AND RECEPTORS**
  - **W.J. Schneider** (Vienna, Austria)
  - TRANSPORT AND PROCESSING OF VLDL PARTICLES FROM LIVER TO OVARY
  - **F.M. Sacks** (Boston, MA, USA)
  - PHYSIOLOGY AND CARDIOVASCULAR RISK OF APOB LIPOPROTEIN PARTICLE TYPES

- **OBESITY AND METABOLIC SYNDROME**
  - **Y. Matsuzawa** (Osaka, Japan)
  - ADIPOCYTKINES AND METABOLIC SYNDROME
  - **A. Avogaro** (Padua, Italy)
  - INSULIN RESISTANCE AND VASCULAR DISEASE: THE ROLE OF INSULIN BEYOND THE RISK FACTORS

- **NUTRITION AND LIFESTYLE TO REDUCE CARDIOVASCULAR RISK**
  - **M.B. Katan** (Wageningen, The Netherlands)
  - DETERMINANTS OF THE CONVERSION OF DIETARY ALPHA LINOLENIC ACID INTO EPA AND DHA IN HUMANS
  - **D.J. Jenkins** (Toronto, ON, Canada)
  - THE PORTFOLIO DIETARY APPROACH TO CHOLESTEROL REDUCTION
• Insulin Resistance and Lipotoxicity
  R. Eckel (Denver, CO, USA)
  Lipoprotein/Free Fatty Acid Partitioning in Skeletal Muscle and Insulin Resistance

S. Del Prato (Pisa, Italy)
Type 2 Diabetes: A Glucose or Lipid Disease?

• Lipoprotein Metabolism
  D.J. Rader (Philadelphia, PA, USA)
  Endothelial Lipase as a Potential Pharmacologic Target for HDL and Atherosclerosis

C.J. Packard (Glasgow, UK)
Regulation of Apolipoprotein B Metabolism in the Metabolic Syndrome

• Cardiometabolic Risk Assessment and New Clinical Markers
  M.A. Albert (Boston, MA, USA)
  C-Reactive Protein and Cardiovascular Risk

A. Mantovani (Milan, Italy)
The Long Pentraxin PTX3: Role as a Multifunctional Humoral Pattern Recognition Receptor and as a Marker in Cardiovascular Pathology

• Multiple Treatment of Hyperlipidemia and Cardiovascular Risk Reduction
  C.M. Ballantyne (Houston, TX, USA)
  Rationale for Targeting Multiple Lipid Pathways for Optimal Cardiovascular Risk Reduction

J.J.P. Kastelein (Amsterdam, The Netherlands)
Modifying Plasma LDL and HDL Cholesterol, What Combinations are Available in the Future

• Genomics and Proteomics in Atherosclerosis
  M.A. Gimbrone (Boston, MA, USA)
  Endothelial Phenotypes in Health and Disease: Genomic Approaches

A. Hamsten (Stockholm, Sweden)
Molecular Genetic Studies on the Role of Proteases in Cardiovascular Disease

• Genetic Approaches and Stem Cell in Cardiovascular Therapy
  M.K. Brenner (Houston, TX, USA)
  Regulatory Requirements for Clinical Studies of Cell and Gene Therapy for Cardiovascular Disorders

G. Condorelli (Rome, Italy)
Genetic and “Stem Cell” Based Approaches for Heart Failure Treatment: Promises and Reality
• **DRUGS AFFECTING LDL AND TRIGLYCERIDES**
  E. Stein, A. Sniderman and P. Laskarzewski (Highland Drive, KY, USA)
  ASSESSMENT OF REACHING GOAL IN PATIENTS WITH COMBINED HYPER-LIPIDEMIA: LDL, non-HDL, Apo B OR RATIOS?

  A. Mezzetti (Chieti, Italy)
  ROLE OF STATINS IN ATHEROSCLEROTIC PLAQUE STABILIZATION: BEYOND CHOLESTEROL

• **DRUGS AFFECTING HDL CHOLESTEROL**
  W.V. Brown (Atlanta, GA, USA)
  IS PERIPHERAL VASCULAR DISEASE RISK ATTRIBUTABLE TO LOW HDL OR HIGH TRIGLYCERIDES?

  G. Franceschini (Milan, Italy)
  HDL MIMETICS FOR CARDIOPROTECTION AGAINST ISCHEMIA-REPERFUSION INJURY

• **PLEIOTROPIC EFFECTS OF LIPID MODIFYING DRUGS**
  P. Ganz (Boston, MA, USA)
  PLEIOTROPIC EFFECTS OF STATINS

  F. Bernini (Parma, Italy)
  MODULATION OF CELLULAR CHOLESTEROL TRAFFICKING BY LIPID AFFECTING DRUGS

• **DRUG METABOLISM AND PHARMACOGENETICS**
  E.J. Schaefer (Boston, MA, USA)
  PHARMACOGENETICS OF STATINS AND FIBRATES

  A. Corsini (Milan, Italy)
  THE CLEARANCE OF STATINS AND ITS RELEVANCE IN DRUG-DRUG INTERACTION
B) SPONSORED SYMPOSIA (Preliminary list of topics and speakers)

- **THE METABOLIC SYNDROME: A PUBLIC HEALTH ISSUE** (Definition, Prevalence and Therapy)
  Chairs: **A.L. Catapano** (Milan, Italy) - **P. Libby** (Boston, MA, USA)
  Speakers: **P.H.R. Barrett** (Perth, Australia) - **Després J.-P.** (Ste-Foy, QC, Canada) - **J.-C. Fruchart** (Lille, France) - **S.M. Grundy** (Dallas, TX, USA) - **M.-R. Taskinen** (Helsinki, Finland)

- **REDUCING CARDIOVASCULAR RISK - WHAT DOES THE FUTURE HOLD?**
  Chairs: **C.M. Ballantyne** (Houston, TX, USA) - **Barter P.** (Camperdown, Australia)
  Speakers: **M.J. Chapman** (Paris, France) - **A. Gaw** (Glasgow, UK) - **Stein E.** (Highland Drive, KY, USA) - **A. Zambon** (Padua, Italy)

- **STATINS AND BROADENING THE SCOPE OF CARDIOVASCULAR BENEFITS: LDL LOWERING AND BEYOND**
  Chairs: **A.M. Gotto, Jr.** (New York, NY, USA) - **R. Paoletti** (Milan, Italy)
  Speakers: **D.J. Betteridge** (London, UK) - **A.M. Gotto, Jr.** (New York, NY, USA) - **P. Libby** (Boston, MA, USA) - **S.E. Nissen** (Cleveland, OH, USA) - **N.R. Poulter** (London, UK)

- **DUAL INHIBITION: SHAPING THE FUTURE OF LIPID MANAGEMENT**
  Chairs: **A.L. Catapano** (Milan, Italy) - **T. Pedersen** (Oslo, Norway)
  Speakers: **E. Bruckert** (Paris, France) - **H.R. Davis, Jr.** (Kenilworth, NJ, USA) - **T. Pedersen** (Oslo, Norway) - **T. Sudhop** (Bonn, Germany)

- **THE PLAQUE: INFLAMMATION AND PLAQUE INSTABILITY**
  Chairs: **C.M. Ballantyne** (Houston, TX, USA) - **R. Paoletti** (Milan, Italy)
  Speakers: **C.M. Ballantyne** (Houston, TX, USA) - **F. Crea** (Rome, Italy) - **F. Mach** (Geneva, Switzerland) - **K. Miyauchi** (Tokyo, Japan) - **M. Yoshida** (Tokyo, Japan)

- **CARDIOVASCULAR RISK AND DIABETES MANAGEMENT - DIAGNOSIS AND TREATMENT IN SPECIAL PATIENT POPULATIONS**
  Chairs: **J.-C. Fruchart** (Lille, France) - **A.M. Gotto, Jr.** (New York, NY, USA)
  Speakers: **B.M. Buckley** (Cork, Ireland) - **J.-C. Fruchart** (Lille, France) - **D.P. Kotler** (New York, NY, USA) - **G.J. L’Italien** (Wallingford, CT, USA) - **J.W. Newcomer** (St. Louis, MO, USA)
C) SATELLITE SYMPOSIUM

- MODERATE ALCOHOL CONSUMPTION AND HUMAN HEALTH: AN UPDATED OVERVIEW

  Chairpersons: Rimm E. (Boston, USA)
  Paoletti R. (Milan, Italy)

Gronbaek M. (Copenhagen, Denmark)
ALCOHOL AND CARDIOVASCULAR DISEASES: RECENT EPIDEMIOLOGICAL DATA

Crea F. (Rome, Italy)
MECHANISMS OF ANTIATHEROSCLEROTIC EFFECTS OF ALCOHOL: FOCUS ON ANTI-INFLAMMATORY ACTION

Rimm E. (Boston, USA)
NON-CARDIOVASCULAR EFFECTS OF MODERATE ALCOHOL CONSUMPTION

Visioli F. (Milan, Italy)
NON-ALCOHOLIC COMPOUNDS OF ALCOHOLIC BEVERAGES: BIOLOGICAL AND PREVENTIVE EFFECTS

Paoletti R. (Milan, Italy)
CLOSING REMARKS
List of topics for WORKSHOPS, ORAL COMMUNICATIONS, AND POSTERS:

**Lipids and Lipoproteins**
1. Lipids
2. Lipoproteins and Atherosclerosis
3. HDL
4. TG-Rich Lipoproteins
5. LDL
6. Lipoprotein Metabolism
7. Lipids, Lipoproteins, and Stroke
8. Lipid Transfer Proteins and Lipases
9. Bile Acid Metabolism
10. Cholesterol Metabolism
11. ABC Transporters
12. Fatty Acids, Plasma Lipids and Atherosclerosis
13. Modified Lipoproteins

**Nutrition and Life Style**
14. Nutrition and Cardiovascular Risk
15. Life Style and Cardiovascular Risk
16. Nutriceuticals
17. Obesity

**The Atherosclerotic Plaque**
18. New Markers for Cardiovascular Risk
19. Thrombosis and Atherosclerosis
20. Peripheral Arterial Disease
21. Inflammation and Atherosclerosis
22. Antioxidants
23. Advances in Determining the Atherosclerotic Burden
24. Lipoproteins, Extra Cellular Matrix and Plaque Stability

**Diabetes and the Metabolic Syndrome**
25. Diabetes
26. Insulin Resistance and Lipotoxicity
27. The Metabolic Syndrome

**PPARs and Transcriptional Regulation**

**Cardiovascular Risk Assessment and Treatment**
28. Cardiovascular Risk Assessment
29. International Guidelines
30. Multiple Treatment of Hyperlipidemia and Cardiovascular Risk Reduction
31. Pharmacoeconomics

**Genomics, Cellular and Gene Therapy**
32. Genomics and Proteomics in Atherosclerosis
33. Gene Targeting
34. Gene Therapy
35. Bone Marrow Cells in the Therapy of Cardiovascular Diseases

**Lipid Lowering Therapy**
36. Lipid Lowering Drugs
37. Drugs Affecting Plasma Triglycerides
38. Drugs Affecting HDL Cholesterol
39. New Lipid Lowering and Antiatherosclerotic Drugs
40. Hypolipidemic Treatment
41. Pleiotropic Effects of Lipid Lowering Drugs
42. Drug Metabolism and Pharmacogenetics
43. Drug Interactions
GENERAL INFORMATION

The Advance Programme of the Symposium is located at:
http://www.lorenzinifoundation.org/dalm2004/
Registration and Hotel Accommodation forms may be downloaded from the website.

ABSTRACT SUBMISSION DEADLINE: JUNE 10, 2004

SCIENTIFIC-ORGANIZING SECRETARIATS:

Fondazione Giovanni Lorenzini / DALM 2004 – Via A. Appiani, 7 – 20121 Milan (ITALY)
Phone: (+39 02) 29006267 – Fax: (+39 02) 29007018 – Email: dalm@lorenzinifoundation.org

Giovanni Lorenzini Medical Foundation / DALM 2004 – 6535 Fannin, M.S. A-601 –
Houston, Texas 77030 (USA) - Phone: (+1-713) 7970401 – Fax: (+1-713) 7968853 –
Email: dalm@bcm.tmc.edu